Susan Guo

Vesatolimod, a toll-like receptor 7 agonist, induces immune activation in virally suppressed adults with HIV-1.

T. Wrin, J. Mellors, R. Begley, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment Week 144 Results

P. Sax, M. Das, A. Clarke, 2017, Journal of acquired immune deficiency syndromes.

HIV & Hepatitis in the Americas 28–30 April 2016, Mexico City, Mexico

N. Volkow, K. Tashima, D. Podzamczer, 2016, Journal of the International AIDS Society.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials

D. Podzamczer, E. Negredo, H. Stellbrink, 2019, AIDS.

The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy

T. Wrin, J. Mellors, R. Begley, 2021, Science Translational Medicine.